PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50% Convertible Senior Notes due 2029 (the “New Notes”), (ii) issue 20,451,570 shares (the “Shares”) of PacBio's common stock (“common stock”), and (iii) make a cash payment in the amount of $50 million (the “Cash Consideration”) in exchange for $459 million principal amount of the 2028 Notes (the “Exchange Transaction”), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about November 21, 2024, subject to customary closing conditions. “This transaction meaningfully reduces and extends the duration of our long-term debt while balancing shareholder dilution and impact to our cas
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Scotiabank from $7.00 to $6.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
PACB
Earnings
- 11/7/24 - Beat
PACB
Sec Filings
- 12/13/24 - Form 8-K
- 12/13/24 - Form 8-K/A
- 12/10/24 - Form SCHEDULE
- PACB's page on the SEC website